Recognizing this challenge, the goal of this study is to explore if the combination of the PI-RADS protocol and prostate-specific antigen density (PSAD) can differentiate between indolent and clinically significant prostate cancer in biopsy-naïve patients and provide additional risk stratification for a more accurate diagnostic decision. Here, KLK3 is linked to prostate cancer.